Back Login to subscribe 🔔 Set Alert

FATE Fate Therapeutics, Inc. Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Fate Therapeutics shares are trading lower. The company presented clinical data this weekend featuring its off-the-shelf CAR T-cell program FT836 at ASCO Annual Meeting.	65.71%
	Fate Therapeutics Presents Clinical Data Featuring Off-The-Shelf CAR T-Cell Program FT836 At 2026 ASCO Annual Meeting	90.9%
	Fate Therapeutics shares are trading higher. The company announced data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting	58.13%
	Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings	80.19%
	Fate Therapeutics shares are trading lower. The company reported Q1 financial results.	83.95%
	Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate	83.78%
	Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting	78.24%
	10 Health Care Stocks Whale Activity In Today's Session	87.44%
	Fate Therapeutics shares are trading higher after the company announced that the FDA has selected FT819 for participation in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program for the treatment of moderate to severe systemic lupus erythematosus.	93.36%
	Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Development And Readiness Pilot Program To Treat Moderate To Severe Systemic Lupus Erythematosus	84.85%

1
2
›